Illumina (ILMN) Coverage Initiated by Analysts at UBS Group

Analysts at UBS Group assumed coverage on shares of Illumina (NASDAQ:ILMN) in a report issued on Tuesday, The Fly reports. The brokerage set a “neutral” rating on the life sciences company’s stock.

Several other equities research analysts have also recently weighed in on ILMN. Piper Jaffray Companies upped their price target on Illumina to $380.00 and gave the company an “overweight” rating in a research report on Tuesday, October 2nd. BidaskClub cut Illumina from a “strong-buy” rating to a “buy” rating in a research report on Thursday, October 4th. Cowen upped their price target on Illumina from $315.00 to $400.00 and gave the company a “positive” rating in a research report on Thursday, September 6th. Argus set a $372.00 price target on Illumina and gave the company a “buy” rating in a research report on Friday, August 10th. Finally, Morgan Stanley upgraded Illumina from an “underweight” rating to an “equal weight” rating and upped their price target for the company from $210.00 to $320.00 in a research report on Tuesday, August 7th. Five equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $322.56.

Shares of NASDAQ:ILMN opened at $325.89 on Tuesday. The company has a current ratio of 2.74, a quick ratio of 2.44 and a debt-to-equity ratio of 0.22. The stock has a market capitalization of $53.96 billion, a P/E ratio of 81.47, a P/E/G ratio of 3.04 and a beta of 0.97. Illumina has a fifty-two week low of $198.21 and a fifty-two week high of $372.61.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Monday, July 30th. The life sciences company reported $1.43 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.11 by $0.32. Illumina had a net margin of 20.88% and a return on equity of 26.64%. The company had revenue of $830.00 million for the quarter, compared to the consensus estimate of $786.88 million. During the same period in the previous year, the firm earned $0.82 EPS. The firm’s quarterly revenue was up 25.4% on a year-over-year basis. On average, analysts expect that Illumina will post 5.46 EPS for the current year.

In other Illumina news, insider Francis A. Desouza sold 2,100 shares of the stock in a transaction on Monday, October 1st. The stock was sold at an average price of $369.61, for a total value of $776,181.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Francis A. Desouza sold 3,300 shares of the stock in a transaction on Thursday, July 12th. The stock was sold at an average price of $300.00, for a total value of $990,000.00. Following the completion of the transaction, the insider now owns 78,635 shares of the company’s stock, valued at approximately $23,590,500. The disclosure for this sale can be found here. Insiders sold 42,483 shares of company stock valued at $14,512,449 in the last ninety days. 0.54% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Fulton Bank N.A. bought a new position in Illumina in the third quarter worth $202,000. United Services Automobile Association raised its holdings in Illumina by 9.5% in the second quarter. United Services Automobile Association now owns 142,672 shares of the life sciences company’s stock worth $39,847,000 after purchasing an additional 12,332 shares in the last quarter. Royal London Asset Management Ltd. bought a new position in Illumina in the second quarter worth $16,905,000. HRT Financial LLC bought a new position in shares of Illumina during the second quarter valued at $266,000. Finally, Advisors Asset Management Inc. increased its holdings in shares of Illumina by 23.8% during the second quarter. Advisors Asset Management Inc. now owns 41,850 shares of the life sciences company’s stock valued at $11,688,000 after acquiring an additional 8,042 shares in the last quarter. Institutional investors and hedge funds own 89.84% of the company’s stock.

About Illumina

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Featured Story: Trading Strategy Examples and Plans

The Fly

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply